Skip to content

Helping patients reclaim a life of possibility

Menu

About us
Contact us

Myeloma and AL Amyloidosis
- About myeloma
- About AL amyloidosis
What we do
- Member and patient community programmes
  Myeloma Awareness Month 2025
  
  MPE Masterclass
  
  Scholarship programme
  
  Myeloma CABs
  
  MPE Myeloma and AL amyloidosis Community Taskforce
  
  Advocate Development Programme
  
  European Young Myeloma Patients Group
  
  Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
  
  Research
  Patient Evidence
  
  Horizon Europe
  
  IMI
  
  Access and Policy
  Myeloma Access Atlas
  
  CEE workgroup on Access
  
  Myeloma and AL amyloidosis Clinical Trial Navigator
  
  EU HTA regulation
Educational Resources
European Myeloma Day
News

Myeloma and AL Amyloidosis
- About myeloma
- About AL amyloidosis
What we do
- Member and patient community programmes
  Myeloma Awareness Month 2025
  
  MPE Masterclass
  
  Scholarship programme
  
  Myeloma CABs
  
  MPE Myeloma and AL amyloidosis Community Taskforce
  
  Advocate Development Programme
  
  European Young Myeloma Patients Group
  
  Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
  
  Research
  Patient Evidence
  
  Horizon Europe
  
  IMI
  
  Access and Policy
  Myeloma Access Atlas
  
  CEE workgroup on Access
  
  Myeloma and AL amyloidosis Clinical Trial Navigator
  
  EU HTA regulation
Educational Resources
European Myeloma Day
News

Day: September 23, 2025

Join our upcoming MPE and ASCERTAIN webinar on cost-effectiveness analysis

MPE, MyelomaSeptember 23, 2025

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2025

Contact
About us
Privacy policy
Terms and conditions
Cookies Policy

About MPE
Contact us
Myeloma and AL Amyloidosis
- About myeloma
- About AL amyloidosis
What we do
Educational Resources
News
European Myeloma Day

PopUp

I am a*
- Patient
- Patient advocate
- Caregiver
- Doctor
Phone
This field is for validation purposes and should be left unchanged.